---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093992"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:34.641340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports Q2 net loss $35M, cash $578M; positive 4D-150 interim data; FDA lifts clinical hold on 4D-310

## Summary
- Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.
- Q2 net loss $35.0M vs $29.6M YoY; R&D expenses rose to $31.9M from $23.6M.
- Phase 2 PRISM 4D-150 in wet AMD: 89% reduction in annualized anti-VEGF injections; 77% injection-free at 24 weeks with 3E10 vg/eye dose.
- FDA removed clinical hold on Phase 1/2 INGLAXA trial for 4D-310 in Fabry disease cardiomyopathy; enrollment to resume H2 2024.
- Senior leadership added: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophth); Ophthalmology Advisory Board formed.

## SEC filing metadata
- accession: 0000950170-24-093992
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/0000950170-24-093992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/fdmt-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093992
- JSON: https://secwatch.observer/filing/0000950170-24-093992.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.